Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience
DOI:
https://doi.org/10.2340/actadv.v102.1088Keywords:
atopic dermatitis, JAK-inhibition, BaricitinibAbstract
Abstract is missing (Short communication)
Downloads
References
Ring J, Zink A, Arents BWM, Seitz IA, Mensing U, Schielein MC, et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol 2019; 33: 1331-1340.
https://doi.org/10.1111/jdv.15634 DOI: https://doi.org/10.1111/jdv.15634
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850-878.
https://doi.org/10.1111/jdv.14888 DOI: https://doi.org/10.1111/jdv.14888
Hajar T, Hanifin JM, Gontijo JRV. New and developing therapies for atopic dermatitis. An Bras Dermatol 2018; 93: 104-107.
https://doi.org/10.1590/abd1806-4841.20187682 DOI: https://doi.org/10.1590/abd1806-4841.20187682
Blauvelt A, Rosmarin D, Bieber T, Simpson EL, Bagel J, Worm M, et al. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. Br J Dermatol 2019; 181: 196-197.
https://doi.org/10.1111/bjd.17703 DOI: https://doi.org/10.1111/bjd.17703
Lauffer F, Ring J. Target-oriented therapy: emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs 2016; 21: 81-89.
https://doi.org/10.1517/14728214.2016.1146681 DOI: https://doi.org/10.1517/14728214.2016.1146681
Paller AS, Bansal A, Simpson EL, Boguniewicz M, Blauvelt A, Siegfried EC, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol 2020; 21: 119-131.
https://doi.org/10.1007/s40257-019-00478-y DOI: https://doi.org/10.1007/s40257-019-00478-y
Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol 2018; 78: S53-S62.
https://doi.org/10.1016/j.jaad.2017.12.019 DOI: https://doi.org/10.1016/j.jaad.2017.12.019
Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat 2020 Nov 22. [Epub ahad of print].
https://doi.org/10.1080/09546634.2020.1839008 DOI: https://doi.org/10.1080/09546634.2020.1839008
Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156: 1333-1343.
https://doi.org/10.1001/jamadermatol.2020.3260 DOI: https://doi.org/10.1001/jamadermatol.2020.3260
Averitt AJ, Weng C, Ryan P, Perotte A. Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations. NPJ Digit Med 2020; 3: 67.
https://doi.org/10.1038/s41746-020-0277-8 DOI: https://doi.org/10.1038/s41746-020-0277-8
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.
https://doi.org/10.1034/j.1600-0625.2001.100102.x DOI: https://doi.org/10.1034/j.1600-0625.2001.100102.x
Singh RK, Finlay AY. Dermatology Life Quality Index use in skin disease guidelines and registries worldwide. J Eur Acad Dermatol Venereol 2020; 34: e822-e824.
https://doi.org/10.1111/jdv.16701 DOI: https://doi.org/10.1111/jdv.16701
Oranje AP. Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score. Curr Probl Dermatol 2011; 41: 149-155.
https://doi.org/10.1159/000323308 DOI: https://doi.org/10.1159/000323308
Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 2012; 92: 497-501.
https://doi.org/10.2340/00015555-1265 DOI: https://doi.org/10.2340/00015555-1265
Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242-255.
https://doi.org/10.1111/bjd.18898 DOI: https://doi.org/10.1111/bjd.18898
Published
How to Cite
License
Copyright (c) 2022 Danielle Rogner, Tilo Biedermann, Felix Lauffer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
